Drug
Js014
Js014: highest development phase Phase 1, developed by Junshi Biosciences. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Junshi Biosciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| JS014, Interleukin 21 and humanized anti-human serum albumin VHH antibody NCT05296772 | Phase 1 | Neoplasm Malignant |
Latest
No recent events.
Follow Js014 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.